公开(公告)号：US20220387382A1

公开(公告)日：2022-12-08

申请号：US17574702

申请日：2022-01-13

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Liming SHAO ,  John Emmerson CAMPBELL ,  Michael Charles HEWITT ,  Una CAMPBELL ,  Taleen G. HANANIA

IPC: A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  C07D333/78 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  A61K45/06

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US11517558B2

公开(公告)日：2022-12-06

申请号：US17097799

申请日：2020-11-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot Hopkins ,  Kenneth Stephen Koblan ,  John R. Snoonian ,  Harold Scott Wilkinson

IPC: A61K31/40 ,  A61P25/24

Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US11370753B2

公开(公告)日：2022-06-28

申请号：US16994835

申请日：2020-08-17

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D207/09

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

公开(公告)号：US20220117899A1

公开(公告)日：2022-04-21

申请号：US17490616

申请日：2021-09-30

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Takumi Asada ,  Gerald R. Galluppi ,  Seth Cabot Hopkins ,  Megumi Maruyama ,  Siriporn Toongsuwan ,  Yuki Tsushima

IPC: A61K9/20 ,  A61K31/40 ,  A61K47/38 ,  A61P25/24 ,  A61P25/18

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US20210267938A1

公开(公告)日：2021-09-02

申请号：US16952401

申请日：2020-11-19

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Liming SHAO ,  John Emmerson CAMPBELL ,  Michael Charles HEWITT ,  Una CAMPBELL ,  Taleen G. HANANIA

IPC: A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  C07D333/78 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  A61K45/06

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US11077090B2

公开(公告)日：2021-08-03

申请号：US15663672

申请日：2017-07-28

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Vadim Alexandrov ,  Carrie A. Bowen ,  Taleen G. Hanania ,  Noel Aaron Powell

IPC: C07D311/76 ,  A61K31/353 ,  A61K31/13 ,  C12P17/06 ,  C07D313/08 ,  A61K45/06 ,  A61K31/352

Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need thereof are also disclosed.

公开(公告)号：US20210205208A1

公开(公告)日：2021-07-08

申请号：US17179053

申请日：2021-02-18

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David BARNHART ,  Michael Clinton KOONS ,  Madhu Sudan HARIHARAN ,  Jordan DUBOW ,  Thierry BILBAULT ,  Anthony John GIOVINAZZO

IPC: A61K9/00 ,  A61K47/02 ,  A61K31/473 ,  A61K47/14 ,  A61K47/26 ,  A61K9/70 ,  A61K47/36 ,  A61K45/06 ,  A61P25/16 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

公开(公告)号：US20210179561A1

公开(公告)日：2021-06-17

申请号：US17181043

申请日：2021-02-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Thierry BILBAULT

IPC: C07D221/18 ,  A61K9/20 ,  A61K9/00

Abstract: Acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, and acid addition salt of apomorphine isobutyrate salts are disclosed. Also disclosed are pharmaceutical compositions (e.g., unit dosage forms, e.g., films) containing acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate. Further disclosed are methods of use of acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate.

公开(公告)号：US20210008030A1

公开(公告)日：2021-01-14

申请号：US16970089

申请日：2019-02-15

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： David BLUM

IPC: A61K31/381 ,  A61K47/38 ,  A61K47/10 ,  A61K47/14

Abstract: Methods and compositions for treating social function disorders are disclosed. The methods involve administering compound of Formula I

公开(公告)号：US10815042B2

公开(公告)日：2020-10-27

申请号：US15616666

申请日：2017-06-07

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Julie A. Cardin ,  Edward Emmett Chapdelaine ,  Steven A. Rau

IPC: B65D75/58 ,  B65B9/00 ,  B65D75/50 ,  B65D75/30 ,  B65D75/52 ,  B65B7/02 ,  B65B9/02 ,  B65B61/00 ,  B65B61/06

Abstract: Embodiments include a package for containing and dispensing a product. The package includes first and second layers; a product seal zone where the first layer is joined to the second layer, the product seal zone having an inner perimeter that defines an unsealed pouch area for containing the product and an outer perimeter; and a header zone adjacent to the outer perimeter of the product seal zone. The header zone includes a first tab; a second tab; a first tab-cut in the first layer within an unsealed portion of the header zone; and a second tab-cut in the second layer within the unsealed portion of the header zone. Other embodiments are also included herein.